Evidence map›Paper›PMID 40270060›Full record

ArticleBMC psychology2025

Cross-sectional and longitudinal validation of the Slovene version of the health-related quality of life questionnaire in patients with Hymenoptera venom allergy (HRQLH-S).

T Močnik, J Šelb, M Peršolja, M Košnik

Abstract readValidation Study
In one paragraph

Article in BMC psychology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Declining venom immunotherapy: patient characteristics and clinical outcomes.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

T MočnikUniversity Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia. tea.mocnik@klinika-golnik.si.
J ŠelbUniversity Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
M PeršoljaUniversity of Primorska, Faculty of Health Sciences, Izola, Slovenia.
M KošnikUniversity Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to determine to what degree venom immunotherapy can affect the Quality of Life (QoL) in patients hypersensitive to the Hymenoptera venom and to validate the Slovene version of the "Vespid Allergy Quality of Life Questionnaire."

methodsThe "Vespid Allergy Quality of Life Questionnaire" (VQLQ), developed by Oude Elberink et al., has become a well-established diagnostic instrument. The Slovene version of the Health-Related Quality of Life Questionnaire for Hymenoptera venom allergy (HRQLH-S) was administered to 288 patients from different groups with a confirmed diagnosis of Hymenoptera venom hypersensitivity to achieve cross-sectional validation. The HRQLH-S results were compared among groups, with an Expectation of Outcome (EoO) questionnaire and a 10-point Likart scale question: (How much is your QoL reduced by being allergic to insect sting?). The questionnaire was administered to 49 patients treated with venom immunotherapy to establish longitudinal validity.

resultsIn cross-sectional study, statistically significant differences (p < 0.001) were observed in patients treated with venom immunotherapy compared to untreated patients. The median (Mdn) was used to compare the groups. Patients that have already been treated recorded a rise in QoL only six months into treatment (Mdn = 3.18), compared to the untreated (Mdn = 4.20). Further noticeable improvements in the QoL were recorded in patients treated for three to five years (Mdn = 2.47). Statistically significant correlations between the HRQLH-S results and the EoO were confirmed in cases of patients with wasp venom hypersensitivity (Q15r = 0.82; Q16r = 0.67; Q17r = 0.63; p < 0.001) and those with honeybee venom hypersensitivity (Q15r = 0.79; Q16r = 0.62; Q17r = 0.64; p < 0.001). The cross-sectional validation yielded a correlation coefficient of 0.96 (Cronbach α). In the longitudinal validation, we showed a significant correlation between EoO and HRQLH-S (Q15r = 0.87; Q16r = 0.77; Q17r = 0.71; p < 0.000.1), with a good internal consistency (Cronbach α = 0.97). Furthermore, we found a significant difference (p < 0.001) in the QoL of pretreatment patients (Mdn = 3.91) compared to the value after five years of treatment (Mdn = 2.06).

conclusionsResults confirm the efficiency of VIT on QoL in patients with Hymenoptera venom hypersensitivity. The HRQLH-S questionnaire proved suitable for measuring QoL in wasp and honeybee venom-allergic patients.

Indexed as

Arthropod VenomsHymenopteraHypersensitivityInsect Bites and StingsQuality of LifeAdultAgedAnimalsCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedReproducibility of ResultsSloveniaArthropod VenomsHymenoptera venom hypersensitivityQuality of lifeVenom immunotherapy

Identifiers

PMID40270060
PMCPMC12016172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.